Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 3/2017

01-09-2017 | Progress in Hematology

DNA damage response and disorders with hematology, oncology and immunology

Author: Shuki Mizutani

Published in: International Journal of Hematology | Issue 3/2017

Login to get access

Excerpt

One of the recent topics in medical science is provided by the research on congenital human disorders with genetic defects in DNA repair and damage response pathway. …
Literature
1.
Mizutani S, Takagi M. XCIND as a genetic disease of X-irradiation hypersensitivity and cancer susceptibility. Int J Hematol. 2013;97(1):37–42.CrossRefPubMed
Metadata
Title
DNA damage response and disorders with hematology, oncology and immunology
Author
Shuki Mizutani
Publication date
01-09-2017
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2017
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-017-2301-6

Other articles of this Issue 3/2017

International Journal of Hematology 3/2017 Go to the issue

Erratum

Erratum to: DNA damage response and hematological malignancy

Original Article

Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study

Original Article

Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment

Original Article

Long-term clinical outcome of spinal Langerhans cell histiocytosis in children

Original Article

Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry

Original Article

Relationship between white blood cell count elevation and clinical response after G-CSF priming chemotherapy for acute myeloid leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits